GeneDx (NASDAQ:WGS - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at BTIG Research in a report issued on Wednesday, Benzinga reports. They presently have a $85.00 price target on the stock. BTIG Research's price objective indicates a potential upside of 66.60% from the stock's previous close.
Several other research analysts have also recently weighed in on the company. Wall Street Zen upgraded GeneDx from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Zacks Research raised GeneDx from a "hold" rating to a "strong-buy" rating in a report on Monday. Canaccord Genuity Group upped their price objective on GeneDx from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. Guggenheim upped their target price on GeneDx from $74.00 to $83.00 and gave the company a "buy" rating in a research note on Thursday, October 1st. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of GeneDx in a research report on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, GeneDx presently has an average rating of "Moderate Buy" and an average price target of $90.14.
Read Our Latest Stock Analysis on WGS
GeneDx Price Performance
NASDAQ:WGS traded up $3.73 during trading hours on Wednesday, reaching $51.02. The stock had a trading volume of 597,446 shares, compared to its average volume of 943,904. The company has a 50 day moving average price of $72.36 and a two-hundred day moving average price of $69.72. GeneDx has a 52 week low of $32.21 and a 52 week high of $170.87. The stock has a market capitalization of $1.53 billion, a PE ratio of -13.46 and a beta of 2.00. The company has a debt-to-equity ratio of 0.60, a quick ratio of 3.85 and a current ratio of 4.16.
GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.21. GeneDx had a positive return on equity of 1.98% and a negative net margin of 24.10%. The firm had revenue of $123.10 million for the quarter, compared to the consensus estimate of $122.93 million. During the same period in the prior year, the business posted ($0.27) earnings per share. As a group, sell-side analysts anticipate that GeneDx will post -0.41 earnings per share for the current fiscal year.
Insider Activity
In other news, CFO Kevin Feeley sold 3,728 shares of the company's stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total transaction of $363,890.08. Following the completion of the sale, the chief financial officer owned 44,945 shares in the company, valued at approximately $4,387,081.45. This represents a 7.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 10,501 shares of the firm's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $97.61, for a total transaction of $1,025,002.61. Following the completion of the sale, the chief executive officer owned 115,476 shares in the company, valued at $11,271,612.36. This represents a 8.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 19,206 shares of company stock worth $1,808,056. 25.17% of the stock is owned by company insiders.
Institutional Trading of GeneDx
Several hedge funds have recently modified their holdings of the stock. Fifth Third Bancorp bought a new stake in shares of GeneDx during the first quarter worth approximately $31,000. Nykredit A S bought a new position in shares of GeneDx during the second quarter worth about $38,000. Sterling Capital Management LLC grew its holdings in shares of GeneDx by 851.4% in the 3rd quarter. Sterling Capital Management LLC now owns 666 shares of the company's stock valued at $48,000 after acquiring an additional 596 shares in the last quarter. Calamos Advisors LLC acquired a new stake in shares of GeneDx in the 3rd quarter valued at approximately $225,000. Finally, AlphaGrep UK Ltd bought a new stake in GeneDx in the 2nd quarter valued at $238,000. 61.72% of the stock is owned by institutional investors.
GeneDx Company Profile
(
Get Free Report)
GeneDx is a genomic testing company focused on helping clinicians diagnose rare and inherited conditions. Its services include whole exome and whole genome sequencing, along with other genetic tests and clinical interpretation of results. The company's testing is used by healthcare providers to support diagnosis and care decisions, particularly for patients with suspected rare genetic disorders. GeneDx also offers testing related to hereditary cancer risk. Founded in 2000 by researchers with experience at the National Institutes of Health, GeneDx has developed its business around applying genomic information in clinical care.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.